VERAXA Biotech (NASDAQ: VRXA) has achieved a significant regulatory milestone, receiving Scientific Advice from Germany's Paul-Ehrlich-Institute (PEI) that supports the proposed development strategy for its lead BiTAC®-TCE program. The feedback, announced on July 20, provides early guidance on the biological rationale, safety assessments, and non-clinical development plan for the company's novel bispecific T-cell engager platform. This regulatory input is expected to reduce development uncertainty by offering greater clarity before advancing toward clinical studies.
The company's BiTAC®-TCE platform represents a next-generation approach to cancer immunotherapy, designed to engage T-cells more effectively against tumor cells. The positive feedback from PEI, Germany's federal authority responsible for vaccines and biomedicines, validates the scientific foundation of the program and aligns the company's development path with regulatory expectations. VERAXA believes this guidance will help streamline future clinical trial applications and mitigate potential risks.
Earlier this year, VERAXA presented encouraging preclinical data for its lead BiTAC®-TCE candidate at the 2026 American Association for Cancer Research (AACR) Annual Meeting, demonstrating potent anti-tumor activity. The company continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (ADCs), and other engineered antibody formats. This latest regulatory milestone follows continued progress in manufacturing and development as VERAXA advances its next-generation antibody therapeutics for cancer.
The Scientific Advice procedure is a key step for drug developers to consult with regulatory experts before initiating clinical trials. It helps companies align their strategies with safety and efficacy requirements, particularly for innovative therapies like BiTAC®-TCE. VERAXA's engagement with PEI underscores the company's commitment to rigorous development and regulatory compliance.
For more information about VERAXA Biotech and its pipeline, visit the company's newsroom at https://ibn.fm/VRXA. The full terms of use and disclaimers are available at http://IBN.fm/Disclaimer.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the company's SEC filings.
